A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia

Pharmacogenetics and Genomics

Volumn 19, Issue 12, 2009, Pages 972-978

  Ginz, Hans F ^a   Rüffert, Henrik ^b   Levano, Soledad ^c   Li Wan Po, Alain ^d   Benthien, Jan ^c   Urwyler, Albert ^c   Girard, Thierry ^c  

^a Division of Operative Critical Care   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; HALOTHANE;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMANY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; MATHEMATICAL MODEL; MOLECULAR GENETICS; MUSCLE CONTRACTURE; PHENOTYPE; PRIORITY JOURNAL; SWITZERLAND;

ADULT; BIOPSY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MALIGNANT HYPERTHERMIA; MODELS, GENETIC; MUSCLE CONTRACTION; MUSCLES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 73949097832     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283339c08     Document Type: Article

References (18)

1. Gronert G, Pessah I, Muldoon S, Tautz T. Malignant hyperthermia. In: Miller R, editor. Miller's anesthesia. 6th ed. Philadelphia: Elsevier, Churchill Livingstone; 2005. pp. 1169-1190.
2. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-1269.
3. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American malignant hyperthermia group. Anesth Analg 1989; 69:511-515.
4. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in ryr1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27:977-989.
5. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86:283-287.
6. Sei Y, Sambuughin N, Muldoon S. Malignant hyperthermia genetic testing in North America working group meeting. Bethesda, Maryland. September 4-5, 2002. Anesthesiology 2004; 100:464-465.
7. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771-779.
8. Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002; 96:232-237.
9. Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwyler A, et al. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009; 30:590-598.
10. Rueffert H, Olthoff D, Deutrich C, Meinecke CD, Froster UG. Mutation screening in the ryanodine receptor 1 gene (ryr1) in patients susceptible to malignant hyperthermia who show definite ivct results: identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692-698.
11. Girard T, Urwyler A, Censier K, Mueller C, Zorzato F, Treves S. Genotype-phenotype comparison of the swiss malignant hyperthermia population. Hum Mutat 2001; 18:357-358.
12. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240:1285-1293.
13. Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2009.
14. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European malignant hyperthermia group. Acta Anaesthesiol Scand 1997; 41:955-966.
15. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632-652.
16. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85:118-128.
17. Islander G, Rydenfelt K, Ranklev E, Bodelsson M. Male preponderance of patients testing positive for malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 2007; 51:614-620.
18. Robinson RL, Anetseder MJ, Brancadoro V, Van Broekhoven C, Carsana A, Censier K, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342-348.